Xbrane Biopharma (Q3 initial take): Strong delivery, financing in focus - Redeye
Bildkälla: Stockfoto

Xbrane Biopharma (Q3 initial take): Strong delivery, financing in focus - Redeye

Redeye gives an initial take on Xbrane's Q3 report, which came in better than expected in terms of revenues and EBIT.

Redeye gives an initial take on Xbrane's Q3 report, which came in better than expected in terms of revenues and EBIT.
Börsvärldens nyhetsbrev